Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2...

Descrición completa

Detalles Bibliográficos

Principais autores:	Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Assuntos:	ANV419 cancer immunotherapy effector T cells IL-2Rβγ agonist immunocytokine immunotherapy
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2381891
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!